Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Oct 8;10(10):CD011611.
doi: 10.1002/14651858.CD011611.pub3.

Ketamine and other glutamate receptor modulators for depression in adults with bipolar disorder

Rebecca L Dean  1 , Tahnee Marquardt  1 , Claudia Hurducas  1 , Styliani Spyridi  2 , Annabelle Barnes  3 , Rebecca Smith  4 , Philip J Cowen  5 , Rupert McShane  5 , Keith Hawton  6 , Gin S Malhi  7 , John Geddes  4 , Andrea Cipriani  5
Affiliations

Ketamine and other glutamate receptor modulators for depression in adults with bipolar disorder

Rebecca L Dean et al. Cochrane Database Syst Rev. .

Abstract

Background: Glutamergic system dysfunction has been implicated in the pathophysiology of bipolar depression. This is an update of the 2015 Cochrane Review for the use of glutamate receptor modulators for depression in bipolar disorder.

Objectives: 1. To assess the effects of ketamine and other glutamate receptor modulators in alleviating the acute symptoms of depression in people with bipolar disorder. 2. To review the acceptability of ketamine and other glutamate receptor modulators in people with bipolar disorder who are experiencing depressive symptoms.

Search methods: We searched the Cochrane Central Register of Controlled Trials (CENTRAL), Ovid MEDLINE, Embase and PsycINFO all years to July 2020. We did not apply any restrictions to date, language or publication status.

Selection criteria: RCTs comparing ketamine or other glutamate receptor modulators with other active psychotropic drugs or saline placebo in adults with bipolar depression.

Data collection and analysis: Two review authors independently selected studies for inclusion, assessed trial quality and extracted data. Primary outcomes were response rate and adverse events. Secondary outcomes included remission rate, depression severity change scores, suicidality, cognition, quality of life, and dropout rate. The GRADE framework was used to assess the certainty of the evidence.

Main results: Ten studies (647 participants) were included in this review (an additional five studies compared to the 2015 review). There were no additional studies added to the comparisons identified in the 2015 Cochrane review on ketamine, memantine and cytidine versus placebo. However, three new comparisons were found: ketamine versus midazolam, N-acetylcysteine versus placebo, and riluzole versus placebo. The glutamate receptor modulators studied were ketamine (three trials), memantine (two), cytidine (one), N-acetylcysteine (three), and riluzole (one). Eight of these studies were placebo-controlled and two-armed. In seven trials the glutamate receptor modulators had been used as add-on drugs to mood stabilisers. Only one trial compared ketamine with an active comparator, midazolam. The treatment period ranged from a single intravenous administration (all ketamine studies), to repeated administration for riluzole, memantine, cytidine, and N-acetylcysteine (with a follow-up of eight weeks, 8 to 12 weeks, 12 weeks, and 16 to 20 weeks, respectively). Six of the studies included sites in the USA, one in Taiwan, one in Denmark, one in Australia, and in one study the location was unclear. All participants had a primary diagnosis of bipolar disorder and were experiencing an acute bipolar depressive episode, diagnosed according to the Diagnostic and Statistical Manual of Mental Disorders fourth edition (IV) or fourth edition text revision (IV-TR). Among all glutamate receptor modulators included in this review, only ketamine appeared to be more efficacious than placebo 24 hours after infusion for response rate (odds ratio (OR) 11.61, 95% confidence interval (CI) 1.25 to 107.74; P = 0.03; participants = 33; studies = 2; I² = 0%, low-certainty evidence). Ketamine seemed to be more effective in reducing depression rating scale scores (MD -11.81, 95% CI -20.01 to -3.61; P = 0.005; participants = 32; studies = 2; I2 = 0%, very low-certainty evidence). There was no evidence of ketamine's efficacy in producing remission over placebo at 24 hours (OR 5.16, 95% CI 0.51 to 52.30; P = 0.72; participants = 33; studies = 2; I2 = 0%, very low-certainty evidence). Evidence on response, remission or depression rating scale scores between ketamine and midazolam was uncertain at 24 hours due to very low-certainty evidence (OR 3.20, 95% CI 0.23 to 45.19). In the one trial assessing ketamine and midazolam, there were no dropouts due to adverse effects or for any reason (very low-certainty evidence). Placebo may have been more effective than N-acetylcysteine in reducing depression rating scale scores at three months, although this was based on very low-certainty evidence (MD 1.28, 95% CI 0.24 to 2.31; participants = 58; studies = 2). Very uncertain evidence found no difference in response at three months (OR 0.82, 95% CI 0.32 to 2.14; participants = 69; studies = 2; very low-certainty evidence). No data were available for remission or acceptability. Extremely limited data were available for riluzole vs placebo, finding only very-low certainty evidence of no difference in dropout rates (OR 2.00, 95% CI 0.31 to 12.84; P = 0.46; participants = 19; studies = 1; I2 = 0%).

Authors' conclusions: It is difficult to draw reliable conclusions from this review due to the certainty of the evidence being low to very low, and the relatively small amount of data usable for analysis in bipolar disorder, which is considerably less than the information available for unipolar depression. Nevertheless, we found uncertain evidence in favour of a single intravenous dose of ketamine (as add-on therapy to mood stabilisers) over placebo in terms of response rate up to 24 hours, however ketamine did not show any better efficacy for remission in bipolar depression. Even though ketamine has the potential to have a rapid and transient antidepressant effect, the efficacy of a single intravenous dose may be limited. We did not find conclusive evidence on adverse events with ketamine, and there was insufficient evidence to draw meaningful conclusions for the remaining glutamate receptor modulators. However, ketamine's psychotomimetic effects (such as delusions or delirium) may have compromised study blinding in some studies, and so we cannot rule out the potential bias introduced by inadequate blinding procedures. To draw more robust conclusions, further methodologically sound RCTs (with adequate blinding) are needed to explore different modes of administration of ketamine, and to study different methods of sustaining antidepressant response, such as repeated administrations.

Trial registration: ClinicalTrials.gov NCT01797575 NCT00088699 NCT00088699 NCT01881763.

PubMed Disclaimer

Conflict of interest statement

RD, TM, CH, SS, AB, RS, PJC, KH and JG report no competing interests.

RM runs NHS and self‐pay ketamine clinics for Oxford Health NHS Foundation Trust. RM has undertaken educational and scientific advisory board work for Janssen Pharmaceuticals to support educational and research activity, no funds are received personally. Janssen supported RM's attendance at the APA conference in New York in 2018. RM has undertaken scientific advisory board work for Sage pharmaceuticals, no funds are directly received. RM is supported by the NIHR Oxford Health Biomedical Research Centre.

GSM has received grant or research support from National Health and Medical Research Council, Australian Rotary Health, NSW Health, American Foundation for Suicide Prevention, Ramsay Research and Teaching Fund, Elsevier, AstraZeneca, Janssen‐Cilag, Lundbeck, Otsuka and Servier; and has been a consultant for AstraZeneca, Janssen‐Cilag, Lundbeck, Otsuka and Servier.

AC has received research and consultancy fees from INCiPiT (Italian Network for Paediatric Trials), CARIPLO Foundation and Angelini Pharma.

Figures

1
1
Study flow diagram.
2
2
Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.
3
3
Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
4
4
Forest plot of comparison: 1 Ketamine versus placebo, outcome: 1.1 Response rate.
5
5
Forest plot of comparison: 2 Ketamine versus Midazolam, outcome: 2.1 Response rate.
6
6
Forest plot of comparison: 2 Memantine versus placebo, outcome: 2.1 Response rate.
7
7
Forest plot of comparison: 4 Cytidine versus placebo, outcome: 4.1 Response rate.
8
8
Forest plot of comparison: 5 N‐acetylcysteine versus placebo, outcome: 5.1 Response rate.
1.1
1.1. Analysis
Comparison 1: Ketamine versus placebo, Outcome 1: Response rate
1.2
1.2. Analysis
Comparison 1: Ketamine versus placebo, Outcome 2: Remission rate
1.3
1.3. Analysis
Comparison 1: Ketamine versus placebo, Outcome 3: Depression rating scale score
1.4
1.4. Analysis
Comparison 1: Ketamine versus placebo, Outcome 4: Acceptability ‐ total dropouts
1.5
1.5. Analysis
Comparison 1: Ketamine versus placebo, Outcome 5: Acceptability ‐ lack of efficacy
2.1
2.1. Analysis
Comparison 2: Ketamine versus Midazolam, Outcome 1: Response rate
2.2
2.2. Analysis
Comparison 2: Ketamine versus Midazolam, Outcome 2: Remission rate
2.3
2.3. Analysis
Comparison 2: Ketamine versus Midazolam, Outcome 3: Depression rating scale score
2.4
2.4. Analysis
Comparison 2: Ketamine versus Midazolam, Outcome 4: Acceptability: adverse effects
2.5
2.5. Analysis
Comparison 2: Ketamine versus Midazolam, Outcome 5: Acceptability: total dropouts
2.6
2.6. Analysis
Comparison 2: Ketamine versus Midazolam, Outcome 6: Suicidality rating scale
3.1
3.1. Analysis
Comparison 3: Memantine versus placebo, Outcome 1: Response rate
3.2
3.2. Analysis
Comparison 3: Memantine versus placebo, Outcome 2: Adverse events: Young Mania Rating Scale (12 weeks)
3.3
3.3. Analysis
Comparison 3: Memantine versus placebo, Outcome 3: Remission rate
3.4
3.4. Analysis
Comparison 3: Memantine versus placebo, Outcome 4: Depression rating scale score
3.5
3.5. Analysis
Comparison 3: Memantine versus placebo, Outcome 5: Suicidality: suicide attempts
3.6
3.6. Analysis
Comparison 3: Memantine versus placebo, Outcome 6: Acceptability ‐ total dropouts
3.7
3.7. Analysis
Comparison 3: Memantine versus placebo, Outcome 7: Acceptability ‐ lack of efficacy
3.8
3.8. Analysis
Comparison 3: Memantine versus placebo, Outcome 8: Acceptability ‐ adverse events
4.1
4.1. Analysis
Comparison 4: Cytidine versus placebo, Outcome 1: Response rate
4.2
4.2. Analysis
Comparison 4: Cytidine versus placebo, Outcome 2: Acceptability ‐ total dropouts
5.1
5.1. Analysis
Comparison 5: N‐acetylcysteine versus placebo, Outcome 1: Response rate
5.2
5.2. Analysis
Comparison 5: N‐acetylcysteine versus placebo, Outcome 2: Adverse events: Young Mania Rating Scale
5.3
5.3. Analysis
Comparison 5: N‐acetylcysteine versus placebo, Outcome 3: Depression rating scale score change
5.4
5.4. Analysis
Comparison 5: N‐acetylcysteine versus placebo, Outcome 4: Suicidality rating scale
6.1
6.1. Analysis
Comparison 6: Riluzole versus placebo, Outcome 1: Acceptability
See this image and copyright information in PMC

Update of

References

References to studies included in this review

Anand 2012 {published data only}
    1. Anand A, Gunn AD, Barkay G, Karne HS, Nurnberger JI, Mathew SJ, et al. Early antidepressant effect of memantine during augmentation of lamotrigine inadequate response in bipolar depression: a double-blind, randomized, placebo-controlled trial. Bipolar Disorders 2012;14:64-70. - PubMed
Bauer 2019 {published and unpublished data}
    1. Bauer I, Green C, Coplo GD, Teixeira AL, Selvaraj, Durkin K, et al. A double-blind, randomized, placebo-controlled study of aspirin and N-Acetylcysteine as adjunctive treatments for bipolar depression. Journal of Clinical Psychiatry 2019;80(1):18m12200. - PubMed
Berk 2019 {published data only}
    1. Berk M, Turner A, Malhi GS, Ng C, Cotton SM, Dodd S, et al. A randomised controlled trial of a mitochondrial therapeutic target for bipolar depression: mitochondrial agents, N-acetylcysteine, and placebo. BMC Medicine 2019;17(1):18. - PMC - PubMed
Diazgranados 2010 {published and unpublished data}
    1. Diazgranados N, Ibrahim L, Brutsche NE, Newberg A, Kronstein P, Khalife S, et al. A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression. Archives of General Psychiatry 2010;67:793-802. - PMC - PubMed
    1. Lally N, Nugent AC, Luckenbaugh DA, Ameli R, Roiser JP, Zarate CA. Anti-anhedonic effect of ketamine and its neural correlates in treatment-resistant bipolar depression. Translational Psychiatry 2014;4:e469. - PMC - PubMed
Ellegaard 2019 {published data only}
    1. Ellegard PK, Licht RW, Nielson RE, Dean OM, Berk M, Poulsen HE, et al. The efficacy of adjunctive N-acetylcysteine in acute bipolar depression: a randomized placebo-controlled study. Journal of Affective Disorders 2019;245:1043-51. - PubMed
Grunebaum 2017 {published and unpublished data}
    1. Grunebaum MF, Ellis SP, Keilp JG, Moitra VK, Cooper TB, Marver JE, et al. Ketamine versus midazolam in bipolar depression with suicidal thoughts: a pilot midazolam-controlled randomized clinical trial. Bipolar Disorders March 2017;19:176-83. [DOI: 10.1111/bdi.12487] - DOI - PubMed
Lee 2014 {published data only}
    1. Lee SY, Chen SL, Chang YH, Chen PS, Huang SY, Tzeng NS, et al. The effects of add-on low-dose memantine on cytokine levels in bipolar II depression: a 12-week double-blind, randomized controlled trial. Journal of Clinical Psychopharmacology 2014;34:337-43. - PubMed
Park 2017 {published data only}
    1. Park LT, Lener MS, Luckenbaugh DA, Hopkins M, Iadorola N, Vieira Rodrigo M, et al. A double-blind, placebo-controlled, pilot study of riluzole monotherapy for acute bipolar depression. Journal of Clinical Psychopharmacology 2017;37(3):355-8. - PMC - PubMed
Yoon 2009 {published data only}
    1. Yoon SJ, Lyoo IK, Haws C, Kim TS, Cohen BM, Renshaw PF. Decreased glutamate/glutamine levels may mediate cytidine's efficacy in treating bipolar depression: a longitudinal proton magnetic resonance spectroscopy study. Neuropsychopharmacology 2009;34(7):1810-8. - PubMed
Zarate 2012 {published and unpublished data}
    1. Lally N, Nugent AC, Luckenbaugh DA, Ameli R, Roiser JP, Zarate CA. Anti-anhedonic effect of ketamine and its neural correlates in treatment-resistant bipolar depression. Translational Psychiatry 2014;4:e469. - PMC - PubMed
    1. Zarate CA, Brutsche NE, Ibrahim L, Franco-Chaves J, Diazgranados N, Cravchik A, et al. Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial. Biological Psychiatry 2012;71:939-46. - PMC - PubMed

References to studies excluded from this review

Alda 2017 {published data only}
    1. Alda M, McKinnon M, Blagdon R, Garnham J, MacLellan S, O'donovan C, et al. Methylene blue treatment for residual symptoms of bipolar disorder: randomised crossover study. British Journal of Psychiatry 2017;210(1):54-60. - PubMed
Berk 2008 {published data only}
    1. Magalhães PV, Dean OM, Bush AI, Copolov DL, Weisinger D, Malhi GS, et al. Systemic illness moderates the impact of N-acetyl cysteine in bipolar disorder. Progress in Neuropsychopharmacology and Biological Psychiatry 2012;37(1):132-5. - PubMed
    1. Berk M, Copolov DL, Dean O, Lu K, Jeavons S, Schapkaitz I, et al. N-acetyl cysteine for depressive symptoms in bipolar disorder-a double-blind randomized placebo-controlled trial. Biological Psychiatry 2008;64(6):468-75. - PubMed
    1. Dean O, Berk M, Cotton SM, Bush AI, Gama CS, Kapczinski F, et al. N-acetyl cysteine (NAC) as an adjunctive therapy for bipolar depression conference poster P35. In: Bipolar disorders. Abstracts of the 9th International Conference on Bipolar Disorder; 2011 June 9-11. Vol. 13. Pittsburgh [PA], 2011:38.
Berk 2010 {published data only}
    1. Berk M, Dodd S, Dean OM, Kohlmann K, Berk L, Malhi GS. The validity and internal structure of the Bipolar Depression Rating Scale: data from a clinical trial of N-acetylcysteine as adjunctive therapy in bipolar disorder. Acta Neuropsychiatrica 2010;22(5):237-42. - PubMed
Castillo 2017 {published data only}
    1. Castillo MF, Murata S, Schwarz M, Martin B, Halaris A. Celecoxib augmentation of escitalopram in treatment-resistant bipolar depression: effects on trycats. Neuropsychopharmacology 2017;43:S176-7.
Chen 2014 {published data only}
    1. Chen SL, Lee SY, Chang YH, Chen PS, Wang TY, Lu RB. Therapeutic effects of add-on low-dose dextromethorphan plus valproic acid in bipolar disorder. European Neuropsychopharmacology 2014;24(11):1753-9. - PubMed
Cocchi 1977 {published data only}
    1. Cocchi R, Fusari A, Lorini G, Roccia L. Acupunctura, "vital" drugs and psychopharmacological agents in the treatment of psychiatric patients with deep depressive disorders, with considerations on the probable neurophysiological mechanisms of the synergism of action [article in Italian]. Minerva Medica 1977;68(33):2309-14. - PubMed
Ehrensing 1978 {published data only}
    1. Ehrensing RH, Kastin AJ. Dose-related biphasic effect of prolyl-leucyl-glycinamide (MIF-I) in depression. American Journal of Psychiatry 1978;135(5):562-6. - PubMed
Ellis 2014 {published data only}
    1. Ellis JS, Luckenbaugh DA, Zarate CA, Furey ML. Effects of ketamine versus scopolamine on individual depression and anxiety symptoms (abstract). Biological Psychiatry 2014;75:127S.
Kantrowitz 2015 {published data only}
    1. Kantrowitz JT, Halberstam B, Gangwisch J. Single-dose ketamine followed by daily D-Cycloserine in treatment-resistant bipolar depression. Journal of Clinical Psychiatry 2015;76(6):737-8. - PubMed
Lee 2012 {published data only}
    1. Lee SY, Chen SL, Chang YH, Chen SH, Chu CH, Huang SY, et al. The DRD2/ANKK1 gene is associated with response to add-on dextromethorphan treatment in bipolar disorder. Journal of Affective Disorders 2012;138:295-300. - PubMed
Lee 2017 {published data only}
    1. Lee SY, Chen SL, Wang TY, Chang YH, Chen PS, Huang SY, et al. The COMT Val158Met Polymorphism is associated with response to add-on dextromethorphan treatment in bipolar disorder. Journal of Clinical Pharmacology 2017;37(1):94-8. - PubMed
Luckenbaugh 2014 {published data only}
    1. Luckenbaugh DA, Niciu MJ, Ionescu DF, Nolan NM, Richards EM, Brutsche NE, et al. Do the dissociative side effects of ketamine mediate its antidepressant effects? Journal of Affective Disorders 2014;159:56-61. - PMC - PubMed

References to ongoing studies

ACTRN12612000830897 {published data only}
    1. ACTRN12612000830897. A double blind, placebo controlled, randomised trial to evaluate the effect of mitochondrial agents, N-acetyl cysteine or placebo on the depressive phase of bipolar disorder. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12612000830897 (first received 23 July 2012).
ISRCTN14689382 {published data only}14689382
    1. ISRCTN14689382. Ketamine augmentation of ECT to improve outcomes in depression. www.isrctn.org/ISRCTN14689382.
NCT01881763 {published data only}
    1. NCT01881763. Comparing therapeutic efficacy and cognitive side effects of electroconvulsive therapy (ECT) using ketamine versus methohexital anesthesia. www.clinicaltrials.gov/show/NCT01881763 (first received 20 June 2013).
NCT03396068 {unpublished data only}
    1. NCT03396068. NRX-101 for maintenance of remission from severe bipolar depression in patients with suicidal ideation. ClinicalTrials.gov/show/NCT03396068 (first received 10 January 2018).
NCT03396601 {unpublished data only}
    1. NCT03396601. NRX100 vs. placebo for rapid stabilization of acute suicidal ideation and behavior in bipolar depression (SevereBD). ClinicalTrials.gov/show/NCT03396601 (first received 11 January 2018).

Additional references

Abdallah 2018
    1. Abdallah C, Averill LA, Gueorguieva R, Goktas S, Purohit P, Ranganathan M, et al. Rapamycin, an immunosuppressant and mTORC1 inhibitor, triples the antidepressant response rate of ketamine at 2 weeks following treatment: a double-blind, placebo-controlled, cross-over, randomized clinical trial. bioRxiv 2018. [DOI: doi.org/10.1101/500959 ]
Alberich 2017
    1. Alberich S, Martínez-Cengotitabengoa M, López P, Zorrilla I, Núñez N, Vieta E, et al. Efficacy and safety of ketamine in bipolar depression: a systematic review. Revista de Psiquiatría y Salud Mental 2017;10(2):104-12. [DOI: 10.1016/j.rpsm.2016.05.005] - DOI - PubMed
Altman 1996
    1. Altman DG, Bland JM. Detecting skewness from summary information. BMJ 1996;313(7066):1200. - PMC - PubMed
APA 1980
    1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 3rd edition. Washington D.C.: American Psychiatric Association, 1980.
APA 1987
    1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 3rd edition. Washington D.C.: American Psychiatric Association, 1987.
APA 1994
    1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th edition. Washington, D.C.: American Psychiatric Association, 1994.
APA 2000
    1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders - Text Revision (DSM-IV-TR). 4th edition. Washington, D.C.: American Psychiatric Association, 2000.
APA 2013
    1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th edition. Arlington (VA): American Psychiatric Association, 2013.
Arroll 2009
    1. Arroll B, Elley CR, Fishman T, Goodyear-Smith FA, Kenealy T, Blashki G, et al. Antidepressants versus placebo for depression in primary care. Cochrane Database of Systematic Reviews 2009, Issue 3. Art. No: CD007954. [DOI: 10.1002/14651858.CD007954] - DOI - PMC - PubMed
Atkins 2004
    1. Atkins D, Best D, Briss PA, Eccles M, Falck-Ytter Y, Flottorp S, et al, GRADE Working Group. Grading quality of evidence and strength of recommendations. BMJ 2004;328(7454):1490. - PMC - PubMed
Bandelow 2006
    1. Bandelow B, Baldwin DS, Dolberg OT, Andersen HF, Stein DJ. What is the threshold for symptomatic response and remission for major depressive disorder, panic disorder, social anxiety disorder, and generalized anxiety disorder? Journal of Clinical Psychiatry 2006;67(9):1428–34. - PubMed
Bauer 2014
    1. Bauer IE, Pascoe MC, Wollenhaupt-Aguiar B, Kapczinski F, Soares JC. Inflammatory mediators of cognitive impairment in bipolar disorder. Journal of Psychiatric Research 2014;56:18-27. - PMC - PubMed
Berton 2006
    1. Berton O, Nestler EJ. New approaches to antidepressant drug discovery: beyond monoamines. Nature Reviews. Neuroscience 2006;7(2):137–51. - PubMed
Bonaventura 2021
    1. Bonaventura J, Lam S, Carlton M, Boehm MA, Gomez JL, Solís O, et al. Pharmacological and behavioral divergence of ketamine enantiomers: implications for abuse liability. Molecular Psychiatry 2021;15 April:Epub ahead of print. [DOI: 10.1038/s41380-021-01093-2] - DOI - PMC - PubMed
Brookes 2001
    1. Brookes ST, Whitley E, Peters TJ, Mulheran PA, Egger M, Davey Smith G. Subgroup analyses in randomized controlled trials: quantifying the risks of false-positives and false-negatives. Health Technology Assessment 2001;5(33):1–56. - PubMed
Brookes 2004
    1. Brookes ST, Whitely E, Egger M, Smith GD, Mulheran PA, Peters TJ. Subgroup analyses in randomized trials: risks of subgroup-specific analyses; power and sample size for the interaction test. Journal of Clinical Epidemiology 2004;57(3):229-36. - PubMed
Caddy 2015
    1. Caddy C, Amit BH, McCloud TL, Rendell JM, Furukawa TA, McShane R, et al. Ketamine and other glutamate receptor modulators for depression in adults. Cochrane Database of Systematic Reviews 2015, Issue 9. Art. No: CD011612. [DOI: 10.1002/14651858.CD011612.pub2] - DOI - PubMed
Chitty 2013
    1. Chitty KM, Lagopoulos J, Lee RS, Hickie IB, Hermens DF. A systematic review and meta-analysis of proton magnetic resonance spectroscopy and mismatch negativity in bipolar disorder. European Neuropsychopharmacology 2013;23(11):1348–63. [DOI: 10.1016/j.euroneuro.2013.07.007] - DOI - PubMed
Cipriani 2009
    1. Cipriani A, Furukawa TA, Salanti G, Geddes JR, Higgins JP, Churchill R, et al. Efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet 2009;373(9665):746–58. - PubMed
Cipriani 2010
    1. Cipriani A, La Ferla T, Furukawa TA, Signoretti A, Nakagawa A, Churchill R, et al. Sertraline versus other antidepressive agents for depression. Cochrane Database of Systematic Reviews 2010, Issue 4. Art. No: CD006117. [DOI: 10.1002/14651858.CD006117.pub4] - DOI - PMC - PubMed
Cipriani 2012
    1. Cipriani A, Purgato M, Furukawa TA, Trespidi C, Imperadore G, Signoretti A, et al. Citalopram versus other anti-depressive agents for depression. Cochrane Database of Systematic Reviews 2012, Issue 7. Art. No: CD006534. [DOI: 10.1002/14651858.CD006534.pub2] - DOI - PMC - PubMed
Cipriani 2013a
    1. Cipriani A, Hawton K, Stockton S, Geddes JR. Lithium in the prevention of suicide in mood disorders: updated systematic review and meta-analysis. BMJ 2013;346:f3646. - PubMed
Cipriani 2013b
    1. Cipriani A, Koesters M, Furukawa TA, Nosè M, Purgato M, Omori IM, et al. Duloxetine versus other anti-depressive agents for depression. Cochrane Database of Systematic Reviews 2012, Issue 10. Art. No: CD006533. [DOI: 10.1002/14651858.CD006533.pub2] - DOI - PMC - PubMed
Cipriani 2020
    1. Cipriani A, Ioannidis JPA, Rothwell PM, Glasziou P, Li T, Hernandez AF, et al. Generating comparative evidence on new drugs and devices after approval. Lancet 2020;395(10228):998-1010. [DOI: 10.1016/S0140-6736(19)33177-0] - DOI - PubMed
Cohen 2019
    1. Coehn, BM. Evidence-based drug treatment of acute depression in bipolar disorder. JAMA Psychiatry 2019;76(12):1314-5. - PubMed
Coyle 2015
    1. Coyle CM, Laws KR. The use of ketamine as an antidepressant: a systematic review and meta‐analysis. Human Psychopharmacology: Clinical and Experimental 2015;30(3):152-63. - PubMed
Cunningham 2000
    1. Cunningham MO, Jones RS. The anticonvulsant, lamotrigine decreases spontaneous glutamate release but increases spontaneous GABA release in the rat entorhinal cortex in vitro. Neuropharmacology 2000;39(11):2139-46. [DOI: 10.1016/s0028-3908(00)00051-4] - DOI - PubMed
Dean 2021
    1. Dean RL, Hurducas C, Hawton K, Spyridi S, Cowen PJ, Hollingsworth S, et al. Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder. Cochrane Database of Systematic Reviews 2021, Issue 9. Art. No: CD011612. [DOI: 10.1002/14651858.CD011612.pub3] - DOI - PMC - PubMed
Dozois 2004
    1. Dozois DJ, Dobson KS. Depression. In: Antony MM, Barlow DH, editors(s). Handbook of Assessment and Treatment Planning for Psychological Disorders. New York: Guilford Press, 2004:259-99.
Efthimiou 2019
    1. Efthimiou O. Statistics in pills: meta-analysis of rare events. Evidence Based Mental Health 2019;22(3):102. [DOI: 10.1136/ebmental-2019-300103] - DOI - PMC - PubMed
Egger 1997
    1. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315(7109):629–34. - PMC - PubMed
Elbourne 2002
    1. Elbourne DR, Altman DG, Higgins JP, Curtin F, Worthington HV, Vail A. Meta-analyses involving crossover trials: methodological issues. International Journal of Epidemiology 2002;31(1):140–9. - PubMed
Feighner 1972
    1. Feighner JP, Robins E, Guze SB, Woodruff RA, Winokur G, Munoz R. Diagnostic criteria for use in psychiatric research. Archives of General Psychiatry 1972;26(1):57–63. - PubMed
Furukawa 2002
    1. Furukawa TA, Guyatt GH, Griffith LE. An empirical study of summary effect measures in meta-analyses. International Journal of Epidemiology 2002;31(1):72–6. - PubMed
Furukawa 2005
    1. Furukawa TA, Cipriani A, Barbui C, Brambilla P, Watanabe N. Imputing response rates from means and standard deviations in meta-analysis. International Clinical Psychopharmacology 2005;20(1):49–52. - PubMed
Furukawa 2006
    1. Furukawa TA, Barbui C, Cipriani A, Brambilla P, Watanabe N. Imputing missing standard deviations in meta-analyses can provide accurate results. Journal of Clinical Epidemiology 2006;59(1):7–10. - PubMed
Furukawa 2007a
    1. Furukawa TA, Watanabe N, Omori IM, Montori VM, Guyatt GH. Association between unreported outcomes and effect size estimates in Cochrane meta-analyses. JAMA 2007;297(5):468–70. - PubMed
Furukawa 2007b
    1. Furukawa TA, Akechi T, Azuma H, Okuyama T, Higuchi T. Evidence-based guidelines for interpretation of the Hamilton Rating Scale for Depression. Journal of Clinical Psychopharmacology 2007;27(5):531–4. - PubMed
Geddes 2013
    1. Geddes JR, Miklowitz DJ. Treatment of bipolar disorder. Lancet 2013;381(9878):1672-82. - PMC - PubMed
Gigante 2012
    1. Gigante AD, Bond DJ, Lafer B, Lam RW, Young LT, Yatham LN. Brain glutamate levels measured by magnetic resonance spectroscopy in patients with bipolar disorder: a meta-analysis. Bipolar Disorders 2012;14:478-87. [DOI: doi: 10.1111/j.1399-5618.2012.01033.x] - PubMed
Godlewska 2019
    1. Godlewska BR, Emir UE, Masaki C, Bargiotas T, Cowen PJ. Changes in brain Glx in depressed bipolar patients treated with lamotrigine: a proton MRS study. Journal of Affective Disorders 2019;246:418-21. - PMC - PubMed
Goodwin 2016
    1. Goodwin GM, Haddad PM, Ferrier IN, Aronson JK, Barnes T, Cipriani A, et al. Evidence-based guidelines for treating bipolar disorder: revised third edition recommendations from the British Association for Psychopharmacology. Journal of Psychopharmacology 2016;30(6):495-553. [DOI: 10.1177/0269881116636545] - DOI - PMC - PubMed
GRADEproGDT 2015 [Computer program]
    1. McMaster University (developed by Evidence Prime, Inc.) GRADEproGDT: GRADEpro Guideline Development Tool [www.guidelinedevelopment.org]. Version 2015. Hamilton: McMaster University (developed by Evidence Prime, Inc.), August 28th 2015.
Grady 2017
    1. Grady SE Marsh TA, Tenhouse A, Klein K. Ketamine for the treatment of major depressive disorder andbipolar depression: a review of the literature. Mental Health Clinician 2017;7(1):16-23. - PMC - PubMed
Guaiana 2010
    1. Guaiana G, Barbui C, Cipriani A. Hydroxyzine for generalised anxiety disorder. Cochrane Database of Systematic Reviews 2010, Issue 12. Art. No: CD006815. [DOI: 10.1002/14651858.CD006815.pub2] - DOI - PubMed
Guy 1976
    1. Guy W. ECDEU Assessment Manual for Psychopharmacology. Rockville (MD): U.S. Department of Health and Human Services, 1976.
Guyatt 1998
    1. Guyatt GH, Juniper EF, Walter SD, Griffith LE, Goldstein RS. Interpreting treatment effects in randomised trials. BMJ 1998;316(7132):690–3. - PMC - PubMed
Hamilton 1960
    1. Hamilton M. A rating scale for depression. Journal of Neurology, Neurosurgery and Psychiatry 1960;23:56-62. - PMC - PubMed
Hidalgo‐Mazzei 2019
    1. Hidalgo-Mazzei D, Berk M, Cipriani A, Cleare AJ, Di Florio A, Dietch D, et al. Treatment-resistant and multi-therapy-resistant criteria for bipolar depression: consensus definition. British Journal of Psychiatry 2019;214(1):27-35. - PMC - PubMed
Higgins 2003
    1. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327(7414):557–60. - PMC - PubMed
Higgins 2011a
    1. Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
Higgins 2011b
    1. Higgins JP, Altman DG, Sterne JA (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane–handbook.org.
Higgins 2011c
    1. Higgins JP, Deeks JJ, Altman DG (editors). Chapter 16: Special topics in statistics. In: Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane–handbook.org.
Higgins 2011d
    1. Higgins JP, Deeks JJ (editors). Chapter 7: Selecting studies and collecting data. In: Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane–handbook.org.
Honey 2003
    1. Honey RA, Turner DC, Honey GD, Sharar SR, Kumaran D, Pomarol-Clotet E. Subdissociative dose ketamine produces a deficit in manipulation but not maintenance of the contents of working memory. Neuropsychopharmacology 2003;28:2037–44. - PMC - PubMed
Joseph 2021
    1. Joseph B, Nandakumar AL, Ahmed AT, Gopal N, Murad MH, Frye MA, et al. Prevalence of bipolar disorder in multiple sclerosis: a systematic review and meta-analysis. Evidence-Based Mental Health 2021;24(2):88-94. [DOI: 10.1136/ebmental-2020-300207] - DOI - PMC - PubMed
Judd 2002
    1. Judd LL, Akiskal HS, Schettler PJ, Endicott J, Maser J, Solomon DA, et al. The long-term natural history of the weekly symptomatic status of bipolar I disorder. Archives of General Psychiatry 2002;59(6):530-7. - PubMed
Judd 2003
    1. Judd LL, Akiskal HS, Schettler PJ, Coryell W, Endicott J, Maser JD, et al. A prospective investigation of the natural history of the long-term weekly symptomatic status of bipolar II disorder. Archives of General Psychiatry 2003;60(3):261-9. - PubMed
Kendall 2014
    1. Kendall T, Morriss R, Mayo-Wilson E, Marcus E, Guideline Development Group. Assessment and management of bipolar disorder: summary of updated NICE guidance. BMJ 2014;349:g5673. - PubMed
Kraus 2017
    1. Kraus C, Rabl U, Vanicek T, Carlberg L Popovic A. Administration of ketamine for unipolar and bipolar depression. International Journal of Psychiatry in Clinical Practice 2017;21(1):2-12. - PubMed
Kryst 2020
    1. Kryst J, Kawalec P, Mitoraj AM, Pilc A, Lasoń W, Brzostek T. Efficacy of single and repeated administration of ketamine in unipolar and bipolar depression: a meta-analysis of randomized clinical trials. Pharmacological Reports 2020;72:543-62. [DOI: ] - PMC - PubMed
Kubitz 2013
    1. Kubitz N, Mehra M, Potluri RC, Garg N, Cossrow N Quinn TJ. Characterization of treatment resistant depression episodes in a cohort of patients from a US commercial claims database. PLOS One 2013;8(10):e76882. - PMC - PubMed
Li 2010
    1. Li N, Lee B, Liu RJ, Banasr M, Dwyer JM, Iwata M, et al. mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science 2010;329(5994):959-64. - PMC - PubMed
Li 2018
    1. Li CT, Yang, KC, Lin, WC. Glutamatergic dysfunction and glutamatergic compounds for major psychiatric disorders: evidence from clinical neuroimaging studies. Frontiers in Psychiatry 2018;9:767. - PMC - PubMed
Magni 2013
    1. Magni LR, Purgato M, Gastaldon C, Papola D, Furukawa TA, Cipriani A, et al. Fluoxetine versus other types of pharmacotherapy for depression. Cochrane Database of Systematic Reviews 2013, Issue 7. Art. No: CD004185. [DOI: 10.1002/14651858.CD004185.pub2] - DOI - PMC - PubMed
Malhi 2016
    1. Malhi GS, Byrow Y, Cassidy F, Cipriani A, Demyttenaere K, Frye MA, et al. Ketamine: stimulating antidepressant treatment? BJ Psych Open 2016;11:e5-e9. - PMC - PubMed
Malhi 2018
    1. Malhi GS, Outhred T, Das P, Morris G, Hamilton A, Mannie Z. Modeling suicide in bipolar disorders. Bipolar Disorders 2018;20(4):334-48. - PubMed
Malhi 2020a
    1. Malhi GS, Bell E, Boyce P, Bassett D, Berk M, Bryant R, et al. The 2020 Royal Australian and New Zealand College of psychiatrists clinical practice guidelines for mood disorders: bipolar disorder summary. Bipolar Disorders 2020;22(8):805-21. [DOI: 10.1111/bdi.13036] - DOI - PubMed
Malhi 2020b
    1. Malhi GS, Bell E, Singh AB, Bassett D, Berk M, Boyce P, et al. The 2020 Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders: major depression summary. Bipolar Disorders 2020;22(8):788-804. [DOI: 10.1111/bdi.13035] - DOI - PubMed
Malhi 2020c
    1. Malhi GS, Bell E, Boyce P, Hopwood M, Murray G, Mulder R, et al. The 2020 mood disorders clinical practice guidelines: translating evidence into practice with both style and substance. Australian & New Zealand Journal of Psychiatry 2020;55(9):919-20. [DOI: 10.1177/00048674211010233] - DOI - PubMed
Malhi 2021
    1. Malhi GS, Bell E, Bassett D, Boyce P, Bryant R, Hazell P, et al. The 2020 Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders. Australian & New Zealand Journal of Psychiatry 2021;55(1):7-117. [DOI: 10.1177/0004867420979353] - DOI - PubMed
McIntyre 2020
    1. McIntyre RS, Berk M, Brietzke E, Goldstein BI, López-Jaramillo C, Kessing LV, et al. Bipolar Disorders. Lancet 2020;396(10265):1841-56. - PubMed
McMullen 2021
    1. McMullen EP, Lee Y, Lipsitz O, Lui LM, Vinberg M, et al. Strategies to prolong ketamine's efficacy in adults with treatment-resistant depression. Advances in Therapy 2021;38(6):2795-820. [DOI: 10.1007/s12325-021-01732-8] - DOI - PMC - PubMed
Merikangas 2011
    1. Merikangas KR, Jin R, He JP, Kessler RC, Lee S, Sampson NA, et al. Prevalence and correlates of bipolar spectrum disorder in the World Mental Health Survey Initiative. Archives of General Psychiatry 2011;68(3):241-51. - PMC - PubMed
Mitchell 2011
    1. Mitchell PB, Frankland A, Hadzi-Pavlovic D, Roberts G, Corry J, Wright A, et al. Comparison of depressive episodes in bipolar disorder and in major depressive disorder within bipolar disorder pedigrees. British Journal of Psychiatry 2011;199(4):303-9. - PubMed
Moher 2009
    1. Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA Statement. BMJ 2009;339:2535. - PMC - PubMed
Montgomery 1979
    1. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. British Journal of Psychiatry 1979;134:382–9. - PubMed
Morgan 2010
    1. Morgan CJA, Muetzelfeldt L, Curran HV. Consequences of chronic ketamine self-administration upon neurocognitive function and psychological wellbeing: a 1-year longitudinal study. Addiction 2010;105:121-33. - PubMed
Moriguchi 2019
    1. Moriguchi S, Takamiya A, Noda Y, Horita N, Wada M, Tsugawa S, et al. Glutamatergic neurometabolite levels in major depressive disorder: a systematic review and meta-analysis of proton magnetic resonance spectroscopy studies.. Molecular Psychiatry 2019;24(7):952-64. - PMC - PubMed
Muller 2003
    1. Muller MJ, Himmerich H, Kienzle B, Szegedi A. Differentiating moderate and severe depression using the Montgomery-Asberg depression rating scale (MADRS). Journal of Affective Disorders 2003;77(3):255–60. - PubMed
Murray 2014
    1. Murray CJ, Ortblad KF, Guinovart C, Lim SS, Wolock TM, Roberts DA, et al. Global, regional, and national incidence and mortality for HIV, tuberculosis, and malaria during 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 2014;384(9947):1005-70. - PMC - PubMed
Naughton 2014
    1. Naughton M, Clarke G, O'Leary OF, Cryan JF, Dinan TG. A review of ketamine in affective disorders: current evidence of clinical efficacy, limitations of use and pre-clinical evidence on proposed mechanisms of action. Journal of Affective Disorders 2014;156:24-35. - PubMed
Niciu 2014
    1. Niciu MJ, Henter ID, Luckenbaugh DA, Zarate CA Jr, Charney DS. Glutamate receptor antagonists as fast-acting therapeutic alternatives for the treatment of depression: ketamine and other compounds. Annual Review of Pharmacology and Toxicology 2014;54:119. - PMC - PubMed
Phelps 2009
    1. Phelps LE, Brutsche N, Moral JR, Luckenbaugh DA, Manji HK, Zarate CA Jr. Family history of alcohol dependence and initial antidepressant response to an N-methyl-D-aspartate antagonist. Biological Psychiatry 2009;65(2):181-4. - PMC - PubMed
Pompili 2013
    1. Pompili M, Gonda X, Serafini G, Innamorati M, Sher L, Amore M, Rihmer Z, Girardi P. Epidemiology of suicide in bipolar disorders: a systematic review of the literature. Bipolar Disorders 2013;15(5):457-90. [DOI: 10.1111/bdi.12087] - DOI - PubMed
Purgato 2014
    1. Purgato M, Papola D, Gastaldon C, Trespidi C, Magni LR, Rizzo C, et al. Paroxetine versus other anti-depressive agents for depression. Cochrane Database of Systematic Reviews 2014, Issue 4. Art. No: CD006531. [DOI: 10.1002/14651858.CD006531.pub2] - DOI - PMC - PubMed
RevMan 2014 [Computer program]
    1. The Nordic Cochrane Centre, The Cochrane Collaboration Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
Salvadore 2010
    1. Salvadore G, Quiroz JA, Machado-Vieira R, Henter ID, Manji HK, Zarate CA. The neurobiology of the switch process in bipolar disorder: a review. Journal of Clinical Psychiatry 2010;71(11):1488-501. - PMC - PubMed
Schwartz 2016
    1. Schwartz J, Murrough JW, Iosifescu DV. Ketamine for treatment-resistant depression: recent developments and clinical applications.. Evidence-Based Mental Health. 2016;19(2):35-8. [DOI: doi: 10.1136/eb-2016-102355] - PMC - PubMed
Smith 2018
    1. Smith KA, Cipriani A, Hawton KE. Modelling suicide in bipolar disorders: Limitations and opportunities. Bipolar Disorders 2018;20(6):566-7. [DOI: 10.1111/bdi.12683] - DOI - PubMed
Spitzer 1978
    1. Spitzer RL, Endicott J, Robins E. Research diagnostic criteria: rationale and reliability. Archives of General Psychiatry 1978;35(6):773–82. - PubMed
Stanislaus 2020
    1. Stanislaus S, Vinberg M, Melbye S, Frost M, Busk J, Bardram JE, et al. Daily self-reported and automatically generated smartphone-based sleep measurements in patients with newly diagnosed bipolar disorder, unaffected first-degree relatives and healthy control individuals. Evidence-Based Mental Health 2020;23(4):146-53. [DOI: 10.1136/ebmental-2020-300148] - DOI - PMC - PubMed
Sterne 2000
    1. Sterne JA, Gavaghan D, Egger M. Publication and related bias in meta-analysis: power of statistical tests and prevalence in the literature. Journal of Clinical Epidemiology 2000;53(11):1119–29. - PubMed
Suh 1997
    1. Suh T, Gallo JJ. Symptom profiles of depression among general medical service users compared with specialty mental health service users. Psychological Medicine 1997;27(5):1051–63. - PubMed
Taylor 2014
    1. Taylor DM, Cornelius V, Smith L, Young AH. Comparative efficacy and acceptability of drug treatments for bipolar depression: a multiple-treatments meta-analysis. Acta Psychiatrica Scandinavica 2014;130(6):452-69. - PubMed
Thomas 2010
    1. Thomas SP, Nandhra HS, Jarvaraman A. Systematic review of lamotrigine augmentation of treatment resistant unipolar depression (TRD). Journal of Mental Health 2010;19(2):168-75. - PubMed
Wang 2015
    1. Wang J, Jing L, Toledo-Salas JC, Xu L. Rapid-onset antidepressant efficacy of glutamatergic system modulators: the neural plasticity hypothesis of depression. Neuroscience Bulletin 2015;31(1):75-86. - PMC - PubMed
Ware 1992
    1. Ware JE Jr, Sherbourne CD. The MOS 36-item short form health survey (SF-36). I. Conceptual framework and item selection. Medical Care 1992;30(6):473–83. - PubMed
Ware 1998
    1. Ware JE, Kosinski M, Keller SD. SF-12: How to Score the SF-12. Physical and Mental Health Summary Scales. Lincoln (RI): QualityMetric Inc., 1998.
WHO 1992
    1. World Health Organization (WHO). The ICD-10 Classification of Mental and Behavioural Disorders. Geneva: WHO, 1992.
WHO 2018
    1. World Health Organization (WHO). International statistical classification of diseases and related health problems (11th Revision). Retrieved from https://icd.who.int/browse11/l-m/en.
WHOQOL Group 1998
    1. WHOQOL Group. The World Health Organization quality of life assessment (WHOQOL): Development and general psychometric properties. Social Science and Medicine 1998;46(12):1569–85. - PubMed
Wilkinson 2019
    1. Wilkinson ST, Sanacora G. A new generation of antidepressants: an update on the pharmaceutical pipeline for novel and rapid-acting therapeutics in mood disorders based on glutamate/GABA neurotransmitter systems. Drug Discovery Today 2019;24(2):606-15. - PMC - PubMed
Williams 2018
    1. Williams NR, Heifets BD, Blasey C, Sudheimer K, Pannu J, Pankow H, et al. Attenuation of antidepressant effects of ketamine by opioid receptor antagonism.. American Journal of Psychiatry. 2018;175(12):1205-15. - PMC - PubMed
Wing 1998
    1. Wing JK, Beevor AS, Curtis RH, Park SB, Burns A. Health of the nation outcome scales (HoNOS). Research and development. British Journal of Psychiatry 1998;172:11-8. - PubMed
Witt 2020
    1. Witt K, Potts J, Hubers A, Grunebaum MF, Murrough JW, Loo C, Cipriani A, et al. Ketamine for suicidal ideation in adults with psychiatric disorders: A systematic review and meta-analysis of treatment trials.. Australian and New Zealand JournL of Psychiatry 2020;54(1):29-45. [DOI: <html><body id="body">doi: 10.1177/0004867419883341</body></html>] - PubMed
Zarate 2006
    1. Zarate CA Jr, Singh JB, Quiroz JA, De Jesus G, Denicoff KK, Luckenbaugh DA, et al. A double-blind, placebo-controlled study of memantine in the treatment of major depression. American Journal of Psychiatry 2006;163(1):153-5.. - PubMed
Zavodnick 2012
    1. Zavodnick AD, Ali R. Lamotrigine in the treatment of unipolar depression with and without comorbidities: a literature review. Psychiatric Quarterly 2012;83:371-83. - PubMed

References to other published versions of this review

McCloud 2015
    1. McCloud TL, Caddy C, Jochim J, Rendell JM, Diamond PR, Shuttleworth C, et al. Ketamine and other glutamate receptor modulators for depression in bipolar disorder in adults. Cochrane Database of Systematic Reviews 2015, Issue 9. Art. No: CD011611. [DOI: 10.1002/14651858.CD011611.pub2] - DOI - PubMed
Rendell 2015
    1. Rendell JM, Shuttleworth C, Jochim J, Diamond PR, Brett D, Amit BH, et al. Ketamine and other glutamate receptor modulators for depression in bipolar disorder in adults. Cochrane Database of Systematic Reviews 2015, Issue 4. Art. No: CD011611. [DOI: 10.1002/14651858.CD011611] - DOI - PubMed

Publication types

Associated data